Illumina, Inc. (NASDAQ:ILMN) Receives Consensus Recommendation of "Hold" from Analysts

Key Points

• Illumina, Inc. has received a consensus recommendation of "Hold" from analysts, with three sell, eleven hold, and five buy ratings among the nineteen brokerages covering the stock.
• The average 1-year target price for Illumina is $115.25, with Barclays raising their target to $95, while Royal Bank of Canada set theirs at $124.
• Illumina's stock is currently trading at $98.96, reflecting a 0.5% decrease, with a market capitalization of $15.21 billion and recent earnings outperforming expectations.

Shares of Illumina, Inc. (NASDAQ:ILMN - Get Free Report) have been given an average rating of "Hold" by the nineteen brokerages that are covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a sell recommendation, eleven have assigned a hold recommendation and five have issued a buy recommendation on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $115.25.

Several equities research analysts have weighed in on the company. Barclays upped their target price on Illumina from $90.00 to $95.00 and gave the stock an "underweight" rating in a research note on Thursday, October 2nd. Daiwa Capital Markets cut Illumina from an "outperform" rating to a "neutral" rating and set a $94.00 price target for the company. in a research note on Tuesday, August 12th. Royal Bank Of Canada set a $124.00 price target on Illumina in a research note on Tuesday, September 2nd. Evercore ISI dropped their price target on Illumina from $135.00 to $132.00 and set an "outperform" rating for the company in a research note on Tuesday, October 7th. Finally, Morgan Stanley increased their price target on Illumina from $100.00 to $105.00 and gave the company an "equal weight" rating in a research note on Monday, August 4th.

Illumina Stock Down 0.5%

NASDAQ ILMN opened at $98.96 on Wednesday. The business has a fifty day moving average price of $98.25 and a two-hundred day moving average price of $91.07. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41. Illumina has a fifty-two week low of $68.70 and a fifty-two week high of $156.66. The stock has a market capitalization of $15.21 billion, a PE ratio of 12.53, a PEG ratio of 2.41 and a beta of 1.40.

Illumina (NASDAQ:ILMN - Get Free Report) last released its earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.17. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The firm had revenue of $1.06 billion during the quarter, compared to analysts' expectations of $1.12 billion. During the same period in the prior year, the company earned $0.36 earnings per share. The company's quarterly revenue was down 4.8% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. Equities analysts expect that Illumina will post 4.51 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Rise Advisors LLC lifted its stake in shares of Illumina by 173.6% in the 1st quarter. Rise Advisors LLC now owns 353 shares of the life sciences company's stock valued at $28,000 after acquiring an additional 224 shares during the last quarter. Parkside Financial Bank & Trust increased its holdings in Illumina by 65.7% in the second quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company's stock valued at $28,000 after purchasing an additional 115 shares during the period. Cullen Frost Bankers Inc. acquired a new stake in Illumina in the second quarter valued at $41,000. NewSquare Capital LLC increased its holdings in Illumina by 604.9% in the second quarter. NewSquare Capital LLC now owns 430 shares of the life sciences company's stock valued at $41,000 after purchasing an additional 369 shares during the period. Finally, Golden State Wealth Management LLC increased its holdings in Illumina by 123.2% in the first quarter. Golden State Wealth Management LLC now owns 529 shares of the life sciences company's stock valued at $42,000 after purchasing an additional 292 shares during the period. 89.42% of the stock is currently owned by institutional investors.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.